Skip to content
NKCELLThe NK guide

The biology

How ADCC Links Antibodies and NK Cells

ADCC is a bridge between antibody recognition and NK-cell attack, but CD107a degranulation, cytokine release and target-cell lysis are not interchangeable results. Here is how the lab evidence fits together, and where it stops.

ADCC—antibody-dependent cellular cytotoxicity—is best understood as a bridge with two ends and two kinds of evidence. In the standard model, the antibody's variable region recognizes a target, while its Fc region can engage an NK cell. That engagement can activate the NK cell to release cytotoxic granules. But a lab result showing that the NK cell degranulated is not the same as showing that the target cell was killed. A flow-cytometry method article on human NK cells makes this point directly: CD107a degranulation does not equal target-cell lysis.

The bridge has two ends

The term ADCC is often used as if it were one event. It is not. It describes a relationship between an antibody, a target cell and a cytotoxic immune cell. On the NK-cell side, an Fc receptor can recognize the antibody's Fc region. The NK cell then supplies the killing machinery.

The important word is can. The bridge explains a possible route to NK-cell activation, not a guaranteed outcome in every tissue, assay or person. An antibody binding its target is one event. An NK cell becoming activated is another. A target cell actually dying is a third. Good evidence keeps those steps separate.

CD107a shows degranulation, not automatically killing

CD107a is used as a surface marker of degranulation—the release of cytotoxic granules from inside the NK cell. It is a useful activation readout. The method article on functional analysis of human NK cells by flow cytometry describes CD107a degranulation alongside K562 or target-cell stimulation and cytokine readings. Its authors explicitly note that degranulation is not equivalent to target-cell lysis.

The practical point is that these readouts answer different questions. Did the NK cell respond? Did it release signaling molecules? Did the target cell die? A positive CD107a result can address the first question in a defined assay. It cannot answer the third by itself.

Swipe or scroll to read the full table →

Lab readout What it can show What it does not show on its own
CD107a degranulation NK-cell granule release after stimulation, as an activation readout That the target cell was lysed; the flow-cytometry method article explicitly separates these
Cytokine readings after K562 or target-cell stimulation Whether NK cells secrete signaling molecules in that assay context Clinical benefit or universal killing capacity
Chromium-release cytotoxicity assay A laboratory signal of target-cell damage in a specific experiment That the same result applies to a person, another cell type or another setting

A disease-specific study shows why readouts travel badly

A study of RhoG deficiency, a genetic condition that causes hemophagocytic lymphohistiocytosis, used CD107a, K562 stimulation and chromium-release measures as different functional readouts of human lymphocyte cytotoxicity. Those are laboratory measurements in a specific disease context. Findings from samples with that genetic defect cannot be turned into a general health-check interpretation.

The broader lesson is not that one assay is the real ADCC test. It is that activation, degranulation and killing are separate endpoints that need separate evidence. A result in one assay may support one link in the chain without proving the whole chain.

Fc readouts and mechanism are not the same claim

An Fc-mediated readout can show that an antibody's Fc region engaged an NK-cell activation pathway in a particular assay. That is not the same as showing that an antibody-coated target cell was lysed, and it is certainly not the same as showing clinical benefit.

The mechanism—antibody bridging, NK-cell activation, granule release and target damage—is a model assembled from several measurements. Each measurement has a ceiling. This is why a careful report separates three statements: Fc engagement was detected, NK cells killed targets in a lab assay, and patients did better. The first two can be experimental findings. The third needs clinical evidence that an assay cannot supply.

NK cells listen to more than one signal

A human NK-cell study found that NKG2D engagement by its ligands MICA or ULBP2 triggered nanoscale reorganization of the IL-15 receptor, linking an activating receptor to cytokine signaling. In plain terms, when the NKG2D receptor met certain ligands, the IL-15 receptor rearranged on the membrane at very small scale. That is an in vitro mechanism finding; it does not show clinical efficacy, and it is not an ADCC experiment.

Its value is as a caution. NK-cell activation is not a single switch. ADCC is one route, but the cell's response depends on other receptors, cytokines and context. A lab result that captures one route is not a full portrait of what happens in a person.

How to read an ADCC claim without overreading it

  • Identify the endpoint: Fc engagement, CD107a degranulation, cytokine release, chromium-release cytotoxicity or a clinical outcome.
  • Ask what the assay used: K562 cells, primary NK cells, target-cell lines or disease samples. These answer different questions.
  • Separate in vitro mechanism from clinical benefit. A mechanism in cultured cells can be real and still not prove that a treatment helps patients.
  • If the claim is about a therapy, keep product, disease, study phase and country specific. ADCC alone is not a result.
  • Watch for the shortcut that treats degranulation as killing. The method article warns against exactly that equivalence.

This is general educational information, not medical advice.

Sources and further reading

Keep reading

Follow the next question.

The biology